vs

Side-by-side financial comparison of Ecovyst Inc. (ECVT) and Krystal Biotech, Inc. (KRYS). Click either name above to swap in a different company.

Ecovyst Inc. is the larger business by last-quarter revenue ($199.4M vs $107.1M, roughly 1.9× Krystal Biotech, Inc.). On growth, Ecovyst Inc. posted the faster year-over-year revenue change (34.0% vs 17.5%). Krystal Biotech, Inc. produced more free cash flow last quarter ($75.4M vs $22.9M). Over the past eight quarters, Krystal Biotech, Inc.'s revenue compounded faster (53.8% CAGR vs 18.7%).

Ecovyst Inc. is a global sustainable specialty materials provider that develops and manufactures high-performance catalysts and functional additives. Its offerings serve key segments including industrial manufacturing, consumer goods, and environmental protection, helping clients improve operational efficiency and lower carbon emissions across North America, Europe, and Asia-Pacific markets.

Krystal Biotech, Inc. is a clinical-stage biotechnology company specializing in the research, development and commercialization of novel gene therapies for rare, serious dermatological diseases with high unmet medical needs. It primarily serves patients across North America and Europe, focusing on monogenic skin disorders that lack effective standard treatment options.

ECVT vs KRYS — Head-to-Head

Bigger by revenue
ECVT
ECVT
1.9× larger
ECVT
$199.4M
$107.1M
KRYS
Growing faster (revenue YoY)
ECVT
ECVT
+16.5% gap
ECVT
34.0%
17.5%
KRYS
More free cash flow
KRYS
KRYS
$52.4M more FCF
KRYS
$75.4M
$22.9M
ECVT
Faster 2-yr revenue CAGR
KRYS
KRYS
Annualised
KRYS
53.8%
18.7%
ECVT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ECVT
ECVT
KRYS
KRYS
Revenue
$199.4M
$107.1M
Net Profit
$51.4M
Gross Margin
23.4%
Operating Margin
10.9%
41.5%
Net Margin
48.0%
Revenue YoY
34.0%
17.5%
Net Profit YoY
13.0%
EPS (diluted)
$0.06
$1.69

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ECVT
ECVT
KRYS
KRYS
Q4 25
$199.4M
$107.1M
Q3 25
$204.9M
$97.8M
Q2 25
$176.1M
$96.0M
Q1 25
$143.1M
$88.2M
Q4 24
$148.9M
$91.1M
Q3 24
$153.9M
$83.8M
Q2 24
$154.0M
$70.3M
Q1 24
$141.6M
$45.3M
Net Profit
ECVT
ECVT
KRYS
KRYS
Q4 25
$51.4M
Q3 25
$-79.3M
$79.4M
Q2 25
$6.0M
$38.3M
Q1 25
$-3.6M
$35.7M
Q4 24
$45.5M
Q3 24
$14.3M
$27.2M
Q2 24
$8.3M
$15.6M
Q1 24
$1.2M
$932.0K
Gross Margin
ECVT
ECVT
KRYS
KRYS
Q4 25
23.4%
Q3 25
25.4%
Q2 25
22.8%
Q1 25
13.3%
Q4 24
28.9%
Q3 24
29.3%
Q2 24
27.3%
Q1 24
23.5%
Operating Margin
ECVT
ECVT
KRYS
KRYS
Q4 25
10.9%
41.5%
Q3 25
13.8%
42.3%
Q2 25
9.0%
40.9%
Q1 25
-0.7%
41.0%
Q4 24
15.1%
45.4%
Q3 24
17.9%
26.8%
Q2 24
14.1%
12.2%
Q1 24
9.5%
-14.8%
Net Margin
ECVT
ECVT
KRYS
KRYS
Q4 25
48.0%
Q3 25
-38.7%
81.2%
Q2 25
3.4%
39.9%
Q1 25
-2.5%
40.5%
Q4 24
49.9%
Q3 24
9.3%
32.4%
Q2 24
5.4%
22.2%
Q1 24
0.9%
2.1%
EPS (diluted)
ECVT
ECVT
KRYS
KRYS
Q4 25
$0.06
$1.69
Q3 25
$-0.69
$2.66
Q2 25
$0.05
$1.29
Q1 25
$-0.03
$1.20
Q4 24
$-0.26
$1.53
Q3 24
$0.12
$0.91
Q2 24
$0.07
$0.53
Q1 24
$0.01
$0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ECVT
ECVT
KRYS
KRYS
Cash + ST InvestmentsLiquidity on hand
$197.2M
$496.3M
Total DebtLower is stronger
$392.6M
Stockholders' EquityBook value
$603.4M
$1.2B
Total Assets
$1.3B
$1.3B
Debt / EquityLower = less leverage
0.65×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ECVT
ECVT
KRYS
KRYS
Q4 25
$197.2M
$496.3M
Q3 25
$82.0M
$392.6M
Q2 25
$69.6M
$353.8M
Q1 25
$127.5M
$308.8M
Q4 24
$131.4M
$344.9M
Q3 24
$123.5M
$374.0M
Q2 24
$83.3M
$345.8M
Q1 24
$103.1M
$359.0M
Total Debt
ECVT
ECVT
KRYS
KRYS
Q4 25
$392.6M
Q3 25
$854.8M
Q2 25
$856.6M
Q1 25
$859.0M
Q4 24
$860.8M
Q3 24
$862.7M
Q2 24
$862.4M
Q1 24
$866.2M
Stockholders' Equity
ECVT
ECVT
KRYS
KRYS
Q4 25
$603.4M
$1.2B
Q3 25
$607.9M
$1.1B
Q2 25
$692.4M
$1.0B
Q1 25
$698.7M
$984.7M
Q4 24
$700.5M
$946.4M
Q3 24
$729.4M
$885.8M
Q2 24
$717.3M
$838.9M
Q1 24
$711.4M
$799.2M
Total Assets
ECVT
ECVT
KRYS
KRYS
Q4 25
$1.3B
$1.3B
Q3 25
$1.7B
$1.2B
Q2 25
$1.8B
$1.1B
Q1 25
$1.8B
$1.1B
Q4 24
$1.8B
$1.1B
Q3 24
$1.8B
$982.3M
Q2 24
$1.8B
$917.7M
Q1 24
$1.8B
$853.3M
Debt / Equity
ECVT
ECVT
KRYS
KRYS
Q4 25
0.65×
Q3 25
1.41×
Q2 25
1.24×
Q1 25
1.23×
Q4 24
1.23×
Q3 24
1.18×
Q2 24
1.20×
Q1 24
1.22×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ECVT
ECVT
KRYS
KRYS
Operating Cash FlowLast quarter
$41.8M
$77.5M
Free Cash FlowOCF − Capex
$22.9M
$75.4M
FCF MarginFCF / Revenue
11.5%
70.4%
Capex IntensityCapex / Revenue
9.4%
2.0%
Cash ConversionOCF / Net Profit
1.51×
TTM Free Cash FlowTrailing 4 quarters
$69.9M
$188.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ECVT
ECVT
KRYS
KRYS
Q4 25
$41.8M
$77.5M
Q3 25
$55.3M
$39.7M
Q2 25
$33.0M
$52.7M
Q1 25
$10.3M
$31.0M
Q4 24
$43.5M
$52.8M
Q3 24
$59.9M
$58.9M
Q2 24
$10.0M
$-4.2M
Q1 24
$36.5M
$15.9M
Free Cash Flow
ECVT
ECVT
KRYS
KRYS
Q4 25
$22.9M
$75.4M
Q3 25
$53.2M
$38.0M
Q2 25
$7.8M
$50.8M
Q1 25
$-14.0M
$24.8M
Q4 24
$30.9M
$52.0M
Q3 24
$53.6M
$57.8M
Q2 24
$-9.3M
$-5.3M
Q1 24
$19.1M
$14.6M
FCF Margin
ECVT
ECVT
KRYS
KRYS
Q4 25
11.5%
70.4%
Q3 25
26.0%
38.8%
Q2 25
4.4%
52.9%
Q1 25
-9.8%
28.1%
Q4 24
20.7%
57.1%
Q3 24
34.9%
69.0%
Q2 24
-6.1%
-7.5%
Q1 24
13.5%
32.3%
Capex Intensity
ECVT
ECVT
KRYS
KRYS
Q4 25
9.4%
2.0%
Q3 25
1.0%
1.7%
Q2 25
14.4%
2.0%
Q1 25
16.9%
7.0%
Q4 24
8.5%
0.9%
Q3 24
4.1%
1.2%
Q2 24
12.5%
1.6%
Q1 24
12.3%
2.8%
Cash Conversion
ECVT
ECVT
KRYS
KRYS
Q4 25
1.51×
Q3 25
0.50×
Q2 25
5.52×
1.38×
Q1 25
0.87×
Q4 24
1.16×
Q3 24
4.21×
2.17×
Q2 24
1.20×
-0.27×
Q1 24
29.90×
17.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ECVT
ECVT

Industrial Mining Automotive$101.3M51%
Regeneration And Treatment Services$90.0M45%
Other$8.1M4%

KRYS
KRYS

Segment breakdown not available.

Related Comparisons